Perrigo Q3 adj EPS $0.80 flat YoY; cuts FY25 guide; starts infant formula review

PERRIGO Co plc

2025-Q3 EPS reported -$0.05 revenue$3,143,500,000

Q3 net sales $1.04B (-4.1% YoY); adj EPS $0.80 vs $0.81; reported EPS $0.09 vs -$0.13.
FY25 outlook lowered: net sales growth -2.5% to -3.0%, adj EPS $2.70-$2.80 (5%-9% YoY growth).
Initiates strategic review of infant formula business; continues oral care review; Dermacosmetics sale on track for Q1 2026.
OTC store brand gained dollar, unit, and volume share in 5 of 7 categories despite soft market.
YTD adj operating income up 9.8% to $455M; benefits from Project Energize and Supply Chain Reinvention.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.